

# INVESTMENT DAILY

Monday  
18  
January 2021



Stock Market Indexes	Last	Change	1 Month	YTD	1 Year
Indonesia - JCI	6,373.41	▼ -0.85%	▲ 6.04%	▲ 1.17%	▲ 1.43%
Indonesia - LQ45	988.75	▼ -1.36%	▲ 4.44%	▼ -2.54%	▼ -3.54%
Indonesia - JII	667.74	▼ -0.57%	▲ 4.04%	▼ -4.35%	▼ -3.66%
US - Dow Jones	30,814.26	▼ -0.57%	▲ 2.04%	▲ 7.97%	▲ 6.15%
Europe - Stoxx 600	407.85	▼ -1.01%	▲ 3.82%	▼ -1.92%	▼ -2.81%
Asia ex. Japan - MXXFEJ	848.29	▼ -0.55%	▲ 9.96%	▲ 30.80%	▲ 27.01%
Hong Kong - Hang Seng	28,573.86	▲ 0.27%	▲ 9.03%	▲ 1.36%	▼ -0.69%
Malaysia - KLCI	1,627.01	▼ -0.53%	▼ -2.81%	▲ 2.41%	▲ 2.64%
Philippines - PCOMP	7,238.46	▼ -0.48%	▲ 0.15%	▼ -7.38%	▼ -5.56%
Singapore - STI	3,004.87	▲ 0.16%	▲ 5.19%	▼ -6.76%	▼ -7.74%
South Korea - KOSPI	3,085.90	▼ -2.03%	▲ 11.94%	▲ 40.42%	▲ 38.32%
Taiwan - TWSE	15,616.39	▼ -0.58%	▲ 11.00%	▲ 30.17%	▲ 29.15%
Thailand - SET	1,519.13	▼ -1.10%	▲ 2.84%	▼ -3.74%	▼ -3.92%
<b>Bond Index</b>					
IBPA Indonesia Government Bond Total Return Index	339.11	▲ 0.05%	▼ -0.10%	▲ 13.35%	▲ 12.27%
<b>Exchange Rate</b>					
USD-IDR	14,020.00	▲ 0.28%	▲ 0.71%	▼ -1.11%	▼ -2.37%

Source: Bloomberg. Data based on closing date T-1, and on "change" compared to T-2. During holiday, data will use next working date.



## B POM Explains the Reason Sinovac Vaccine Can Be Used Even though Phase III Clinical Trials Have Not Been Completed

Head of the Food and Drug Supervisory Agency (BPOM) Penny K. Lukito revealed the reason for issuing an emergency use authorization (EUA) or permit for emergency use of the Covid-19 vaccine from Sinovac even though the phase III clinical trial has not been completed. "Vaccines have been permitted even though the clinical trials have not been completed, now that is because there is an approval, emergency use authorization. We can issue them where there is an emergency situation and there is already a declared emergency situation," he said. He explained, although the phase III clinical trial of the Sinovac vaccine has not been completed, the Covid-19 vaccine made by a Chinese pharmaceutical company already has sufficient scientific evidence for use. According to him, this vaccine also has an accountable quality. The Sinovac vaccine has an efficacy rate of 65.3 percent. This means that it meets international standards that vaccines can be used with an efficacy level of at least 50 percent.

Kompas

## BPS: Trade Balance Surplus Last Year Was US \$ 21.74 Billion

Indonesia's trade balance throughout 2020 was a surplus. The Central Statistics Agency (BPS) stated that last year's trade balance surplus was US \$ 21.74 billion. Head of BPS Suhariyanto said that the trade balance surplus over the past year was driven by the value of exports which was still greater than the value of imports. "The export value throughout 2020 is US \$ 163.31 billion. Then the import value is US \$ 141.5 billion," Suhariyanto explained. Even though the value of exports is greater than the value of imports, Indonesia's exports in 2020 actually decreased when compared to the value of exports throughout 2019. The decline was 2.61% yoy. Meanwhile, import values throughout 2020 fell further, namely by 17.34% yoy driven by a decline in imports of both consumer goods, raw goods and capital goods over the past year.

Kontan

## Brazil Gives Emergency Permit for Corona Sinovac-AstraZeneca Vaccine

Brazilian health regulator Anvisa gave emergency approval for two Covid-19 vaccines made by Chinese company Sinovac and British Covishield owned by AstraZeneca-Oxford, Sunday (17/1) local time. After approval, Brazil will start a mass vaccination campaign amid the second wave of the coronavirus pandemic that has killed more than 1,000 people per day in the country. Anvisa also approved the AstraZeneca vaccine and the University of Oxford Covishield vaccine to be used in a country with 209,000 Covid-19 deaths, the second largest in the world behind the United States. Health Minister Eduardo Pazuello announced the government would start distributing vaccines to all 27 states on Monday and start a national inoculation campaign on Wednesday.

CNN Indonesia

Disclaimer : This document is made only as public information, and on specific investment target, individuals specific preference and allocation has not included in this document. You don't have to depend on this document as investment recommendation. If you have interest of anything about investment product, or if you do not have confidence on investment decision, you have to search financial recommendation from your professional advisor. Information that provided in this document are from trustable source, however, Allianz does not guarantee data accuracy. Opinion or prediction can changed without any prior information, and for that Allianz strictly refuse each and every responsibility on statement and guarantation, imply or not imply, stated in here or not stated.

